Spyre CEO Turtle Cameron’s March 2026 Stock Sale: Implications & Investor Takeaway
Spyre CEO Turtle Cameron sells 15,000 shares at premium—insider liquidity strategy amid investor‑conference buzz.
3 minutes to read
Spyre Therapeutics Inc
Spyre’s Insider Options Signal Confidence Ahead of IBD Milestones and Market Upside
Spyre Therapeutics’ new executive option grants signal confidence and long‑term commitment to its IBD antibody pipeline, highlighting potential upside and investor interest.
5 minutes to read